Tan-Alize Kozmetick ve Temizlik Urunleri Sanayi ve Ticaret A.S.
Letter data
- Company
- Tan-Alize Kozmetick ve Temizlik Urunleri Sanayi ve Ticaret A.S.
- Recipient
- Mr. Hakan Tuna | President/Chairman of the Board | Tan-Alize Kozmetick ve Temizlik Urunleri Sanayi ve Ticaret A.S. | No. 32 Omerli Mahallesi, Uran Caddesi | 34799 | Cekmekoy | / | İstanbul | Turkey
- Issue date
- 2024-08-14
- Posted date
- Not available
- FDA office
- Center for Drug Evaluation and Research | CDER
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 659854
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Tan-Alize Kozmetick ve Temizlik Urunleri Sanayi ve Ticaret A.S.
MARCS-CMS 659854 —
August 14, 2024
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Product:
Drugs
Recipient:
Recipient Name
Mr. Hakan Tuna
Recipient Title
President/Chairman of the Board
Tan-Alize Kozmetick ve Temizlik Urunleri Sanayi ve Ticaret A.S.
No. 32 Omerli Mahallesi, Uran Caddesi
34799
Cekmekoy
/
İstanbul
Turkey
Issuing Office:
Center for Drug Evaluation and Research | CDER
United States
Secondary Issuing Offices
United States
Dear Mr. Tuna:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-23-29 dated August 3, 2023.
Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.
The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Reba Gates
Compliance Officer
Division of Drug Quality II
Content current as of:
08/30/2024
Regulated Product(s)
Drugs